Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). - Cunningham,D.; Humblet,Y.; Siena,D. (Proc ASCO, 2003)